MISGAV, Israel, July 3, 2012 /PRNewswire/ --
Stimatix GI Ltd., a leading developer of low-profile innovative solutions for colostomy management, announced today that it was granted CE Mark for its AOS-C2000. Stimatix GI is developing the AOS-C1000 and the AOS-C2000 as part of its colostomy product line that provides voluntary bowel evacuation and improves the quality of life for people with a stoma.
"Obtaining the CE Mark, on schedule, along with the FDA registration completed in April this year, is an additional significant step on the path to setting a new standard in stoma care, and enhancing the quality of life for individuals with colostomies," says David Hanuka, CEO of Stimatix GI.
About Stimatix GI Medical Ltd.
Stimatix GI (http://www.stimatix-gi.com) was founded in June 2009 and is a portfolio company of The Trendlines Group's Misgav Venture Accelerator, Pontifax Venture Capital Fund and Lazarus Israel Opportunities Fund. Stimatix GI develops innovative management devices for people with stoma intended to improve quality of life.
The Trendlines Group (http://www.trendlines.com) establishes, invests in, and develops innovation-based businesses in the medical and agritech fields. Seed-stage investors, Trendlines invests principally through a platform of Israeli government-licensed business accelerators, Misgav Venture Accelerator (http://www.misgav-venture.com) and Mofet Venture Accelerator (http://www.mofet-venture.com). Over the last four years, Trendlines has attracted investments exceeding $150 million.
Dorit Orly +972-052-2525167 | Ofir Shpigel's Media and Public Relations | +972-04-9535030
SOURCE Stimatix GI Ltd